KPIs & Operating Metrics(New)
Growth Metrics

Amgen (AMGN) Gains from Investment Securities (2016 - 2026)

Amgen has reported Gains from Investment Securities over the past 18 years, most recently at $4.0 million for Q1 2026.

  • For Q1 2026, Gains from Investment Securities fell 92.0% year-over-year to $4.0 million; the TTM value through Mar 2026 reached -$14.0 million, down 105.83%, while the annual FY2025 figure was $32.0 million, 81.92% down from the prior year.
  • Gains from Investment Securities for Q1 2026 was $4.0 million at Amgen, up from -$69.0 million in the prior quarter.
  • Over five years, Gains from Investment Securities peaked at $355.0 million in Q4 2023 and troughed at -$492.0 million in Q3 2023.
  • A 5-year average of -$6.5 million and a median of $4.0 million in 2026 define the central range for Gains from Investment Securities.
  • On a YoY basis, Gains from Investment Securities climbed as much as 1443.48% in 2023 and fell as far as 5366.67% in 2023.
  • Year by year, Gains from Investment Securities stood at $23.0 million in 2022, then soared by 1443.48% to $355.0 million in 2023, then dropped by 27.32% to $258.0 million in 2024, then crashed by 126.74% to -$69.0 million in 2025, then surged by 105.8% to $4.0 million in 2026.
  • Business Quant data shows Gains from Investment Securities for AMGN at $4.0 million in Q1 2026, -$69.0 million in Q4 2025, and $45.0 million in Q3 2025.